732 related articles for article (PubMed ID: 25863806)
1. Increased cystatin C levels as a risk factor of cardiovascular events in patients with preserved estimated glomerular filtration rate after elective percutaneous coronary intervention with drug-eluting stents.
Sai E; Shimada K; Miyauchi K; Masaki Y; Kojima T; Miyazaki T; Kurata T; Ogita M; Tsuboi S; Yoshihara T; Miyazaki T; Ohsaka A; Daida H
Heart Vessels; 2016 May; 31(5):694-701. PubMed ID: 25863806
[TBL] [Abstract][Full Text] [Related]
2. Impact of chronic kidney disease on patients with unprotected left main coronary artery disease treated with coronary artery bypass grafting or drug-eluting stents.
Pan Y; Qiu Q; Chen F; Li X; Yu X; Luo Y; Li Q; He J; Gao Y; Zhang X; Ren X
Coron Artery Dis; 2016 Nov; 27(7):535-42. PubMed ID: 27269882
[TBL] [Abstract][Full Text] [Related]
3. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials.
Baber U; Giustino G; Sartori S; Aquino M; Stefanini GG; Steg PG; Windecker S; Leon MB; Wijns W; Serruys PW; Valgimigli M; Stone GW; Dangas GD; Morice MC; Camenzind E; Weisz G; Smits PC; Kandzari D; Von Birgelen C; Mastoris I; Galatius S; Jeger RV; Kimura T; Mikhail GW; Itchhaporia D; Mehta L; Ortega R; Kim HS; Kastrati A; Chieffo A; Mehran R
JACC Cardiovasc Interv; 2016 Jan; 9(1):28-38. PubMed ID: 26762908
[TBL] [Abstract][Full Text] [Related]
4. Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents.
Miao Y; Yu-Jie Z; Zhi-Jian W; Dong-Mei S; Yu-Yang L; Ying-Xin Z; Fei G; Shi-Wei Y; De-An J
Catheter Cardiovasc Interv; 2012 Sep; 80(3):361-7. PubMed ID: 22419375
[TBL] [Abstract][Full Text] [Related]
5. Impact of 3-dimensional bifurcation angle on 5-year outcome of patients after percutaneous coronary intervention for left main coronary artery disease: a substudy of the SYNTAX trial (synergy between percutaneous coronary intervention with taxus and cardiac surgery).
Girasis C; Farooq V; Diletti R; Muramatsu T; Bourantas CV; Onuma Y; Holmes DR; Feldman TE; Morel MA; van Es GA; Dawkins KD; Morice MC; Serruys PW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1250-60. PubMed ID: 24355115
[TBL] [Abstract][Full Text] [Related]
6. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery disease after treatment with sirolimus-eluting stents: insights from the j-Cypher registry.
Toyofuku M; Kimura T; Morimoto T; Hayashi Y; Shiode N; Nishikawa H; Nakao K; Shirota K; Kawai K; Hiasa Y; Kadota K; Nozaki Y; Isshiki T; Sone T; Mitsudo K;
JACC Cardiovasc Interv; 2013 Jul; 6(7):654-63. PubMed ID: 23866178
[TBL] [Abstract][Full Text] [Related]
8. Chronic Kidney Disease in the Second-Generation Drug-Eluting Stent Era: Pooled Analysis of the Korean Multicenter Drug-Eluting Stent Registry.
Lee JM; Kang J; Lee E; Hwang D; Rhee TM; Park J; Kim HL; Lee SE; Han JK; Yang HM; Park KW; Na SH; Kang HJ; Koo BK; Kim HS
JACC Cardiovasc Interv; 2016 Oct; 9(20):2097-2109. PubMed ID: 27692820
[TBL] [Abstract][Full Text] [Related]
9. Impact of Mild-to-Moderate Chronic Kidney Disease on One Year Outcomes after Percutaneous Coronary Intervention.
Grandjean-Thomsen NL; Marley P; Shadbolt B; Farshid A
Nephron; 2017; 137(1):23-28. PubMed ID: 28478459
[TBL] [Abstract][Full Text] [Related]
10. Prognostic values of C-reactive protein levels on clinical outcome after implantation of sirolimus-eluting stents in patients on hemodialysis.
Ishii H; Toriyama T; Aoyama T; Takahashi H; Amano T; Hayashi M; Tanaka M; Kawamura Y; Yasuda Y; Yuzawa Y; Maruyama S; Matsuo S; Matsubara T; Murohara T
Circ Cardiovasc Interv; 2009 Dec; 2(6):513-8. PubMed ID: 20031768
[TBL] [Abstract][Full Text] [Related]
11. Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions.
Abdel-Wahab M; Baev R; Dieker P; Kassner G; Khattab AA; Toelg R; Sulimov D; Geist V; Richardt G
Catheter Cardiovasc Interv; 2013 Feb; 81(2):285-91. PubMed ID: 22431433
[TBL] [Abstract][Full Text] [Related]
12. Impact of renal insufficiency on safety and efficacy of drug-eluting stents compared to bare-metal stents at 6 years.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Valstar G; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P;
Catheter Cardiovasc Interv; 2012 Jul; 80(1):18-26. PubMed ID: 21735520
[TBL] [Abstract][Full Text] [Related]
13. Drug-eluting stents in patients on chronic hemodialysis: paclitaxel-eluting stents vs. limus-eluting stents.
Sardi GL; Loh JP; Torguson R; Laynez-Carnicero A; Kitabata H; Xue Z; Satler LF; Pichard AD; Waksman R
Cardiovasc Revasc Med; 2014 Mar; 15(2):86-91. PubMed ID: 24684759
[TBL] [Abstract][Full Text] [Related]
14. Outcomes in patients with renal impairment undergoing percutaneous coronary intervention and implantation of the Endeavor zotarolimus-eluting stent: 1- and 2-year data from the E-Five Registry.
Rothman MT; Jain AK;
Catheter Cardiovasc Interv; 2012 Nov; 80(6):885-92. PubMed ID: 22517785
[TBL] [Abstract][Full Text] [Related]
15. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
[TBL] [Abstract][Full Text] [Related]
16. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
[TBL] [Abstract][Full Text] [Related]
17. The burden of major adverse cardiac events in patients with coronary artery disease.
Tsai IT; Wang CP; Lu YC; Hung WC; Wu CC; Lu LF; Chung FM; Hsu CC; Lee YJ; Yu TH
BMC Cardiovasc Disord; 2017 Jan; 17(1):1. PubMed ID: 28052754
[TBL] [Abstract][Full Text] [Related]
18. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.
Cassese S; Kufner S; Xhepa E; Byrne RA; Kreutzer J; Ibrahim T; Tiroch K; Valgimigli M; Tölg R; Fusaro M; Schunkert H; Laugwitz KL; Mehilli J; Kastrati A
Clin Res Cardiol; 2016 Jul; 105(7):575-84. PubMed ID: 26689707
[TBL] [Abstract][Full Text] [Related]
19. Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events.
Dupont M; Wu Y; Hazen SL; Tang WH
Circ Heart Fail; 2012 Sep; 5(5):602-9. PubMed ID: 22899766
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
Laynez A; Sardi G; Hauville C; Barbash IM; Pakala R; Torguson R; Xue Z; Satler LF; Pichard AD; Waksman R
Catheter Cardiovasc Interv; 2013 Apr; 81(5):759-65. PubMed ID: 22488756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
